Lenz Therapeutics, Inc. (LENZ) Stock Price & Analysis

Lenz Therapeutics, Inc. (LENZ) rose 2.23% to USD 5.96 as of September 8, 2026 at 03:33 UTC, according to Nexqual real-time market data.

LENZ last closed at USD 5.96; the session ranged USD 5.62–5.97 on volume of 488,956 shares. Market capitalization is —, with a 52-week range of USD 4.54–50.4 (NMS). Source: Nexqual, September 8, 2026 at 03:33 UTC.

Key Statistics (as of September 8, 2026 at 03:33 UTC)

Technical Analysis (LENZ)

Nexqual's technical model rates LENZ "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 03:33 UTC.

From Lenz Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)

Key Strengths & Strategy (as disclosed to the SEC)

• Based on these positive results in our Phase 3 trial, we selected VIZZ as our lead product candidate and submitted a New Drug Application ("NDA") to the FDA in August 2024.
• License and Distribution Agreements." In March 2026, we announced the submission of a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") for the review and approval of VIZZ.
• Our sales strategy empowers ECPs to be actively involved in the diagnosis and treatment of presbyopia for the aging population, including a consumer sampling program described in "Consumer Sampling Strategy." Subsequent to FDA approval and commercial launch of VIZZ, we have seen more ECPs begin to prescribe prescription-based eye drops, which will drive more patients requesting prescriptions who otherwise may not have sought appointments with ECPs for other eye conditions.
• A Drug Master File ("DMF") is on file with the FDA for the API.

Partnerships

• We also entered into a distribution agreement with Lunatus Global Medical Supplies (the "Lunatus Distribution Agreement") to sell VIZZ in a nine-country region in the Middle East, including the United Arab Emirates, Kingdom of Saudi Arabia, Kuwait, Qatar, Bahrain, Oman, Jordan, Lebanon, and Iraq (collectively, the "Middle East").
• In addition, we have entered into a license and collaboration agreement (the "CORXEL License") with CORXEL Pharmaceuticals (formerly known as Ji Xing Pharmaceuticals Hong Kong Limited) ("CORXEL") to develop and commercialize LNZ100 (commercially known as VIZZ in the U.S.) in Greater China, a license and commercialization agreement with Lotus Pharmaceutical Co.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 03:33 UTC. This page is informational and not investment advice.